Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease
Objective: To investigate the effects of safinamide (saf) on synaptic plasticity of spiny projection neurons (SPNs) and the antiparkinsonian effect in dopamine (DA) denervated rats…Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world
Objective: Advanced Parkinson’s disease manifests with “on-off” phenomenon, dyskinesias and increasing symptom severity . Managing it in developing countries is difficult given the low per…An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases
Objective: To describe unusual cause of rhabdomyolysis in the two patients with Parkinson’s disease (PD). Background: Levodopa-induced dyskinesia (LID) is usually seen in advanced stage…Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)
Objective: To evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). Background: LID is…Shedding light on the relationship between dyskinesia assessed by a wearable device and impulsive compulsive behaviour in Parkinson’s disease
Objective: To evaluate the relationship between the presence of dyskinesia objectively detected using a wearable device and the presence of active and past impulsive compulsive…Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist
Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…Non-motor symptoms burden is greater in early Parkinson’s disease patients with motor complications
Objective: To analyze how motor complications are related to non-motor symptoms (NMS) burden in a population of early Parkinson´s disease (PD) patients. Background: It is…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease
Objective: To investigate the relationship of levodopa-induced dyskinesia with ADORA2A gene polymorphisms in PD patients. Background: With the progression of the disease, motor complications and…Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)
Objective: Analysis of dyskinesia as reported by PD diary, adverse events, UPDRS part IV dyskinesia score and examiner rated observation, during a phase 3 study…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 44
- Next Page »